

UNIVERSITY *of* MISSOURI

RESEARCH REACTOR CENTER

March 18, 2015

Mr. Steve Lynch
U.S. Nuclear Regulatory Commission
Office of Nuclear Reactor Regulation
Division of Policy and Rulemaking, Research and Test Reactors Licensing
Office: 0-12F08; Mail Stop: 0-12D20
Washington DC 20555-0001

Dear Mr. Lynch:

The purpose of this letter is to request a meeting with appropriate NRC staff. The objective of the meeting is to provide a technical overview of the recently announced molybdenum 99 project using General Atomics proprietary selective gaseous extraction technology and the University of Missouri Research Reactor (MURR). We envision this meeting requiring several hours to present information and respond to questions. Representatives from MURR as well as General Atomics and Nordion Medical will participate in presenting the technical overview.

While this project is currently in the conceptual design stage, we wish to begin dialogue with NRC staff to help assure the efficiency of the regulatory licensing process. We anticipate this project will require a license amendment to our Reactor License (Class 104c Amended Facility License No. R-103, Docket No. 50-186).

Your consideration of this request and a response at your earliest convenience would be appreciated.

Sincerely,



Ralph A. Butler
Executive Director
University of Missouri Research Reactor Center

